146 related articles for article (PubMed ID: 35126609)
1. The panorama of different faces of mesothelial cells.
Shidham VB
Cytojournal; 2021; 18():31. PubMed ID: 35126609
[TBL] [Abstract][Full Text] [Related]
2. Approach to Diagnostic Cytopathology of Serous Effusions.
Shidham VB; Layfield LJ
Cytojournal; 2021; 18():32. PubMed ID: 35126610
[TBL] [Abstract][Full Text] [Related]
3. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
4. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
5. Cytological diagnosis of metastatic alveolar rhabdomyosarcoma in the ascitic fluid: Report of a case highlighting the diagnostic difficulties.
Nelson AC; Singh C; Pambuccian SE
Cytojournal; 2012; 9():9. PubMed ID: 22574079
[TBL] [Abstract][Full Text] [Related]
6. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
Ascoli V; Bosco D; Carnovale Scalzo C
Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
[TBL] [Abstract][Full Text] [Related]
7. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
8. Cytomorphologic consideration in malignant ascites with renal cell carcinoma: A report of two cases.
Gupta R; Mathur SR; Iyer VK; Kumar A S; Seth A
Cytojournal; 2010 Apr; 7():4. PubMed ID: 20436788
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemistry of effusion fluids: Introduction to SCIP approach.
Shidham VB; Layfield LJ
Cytojournal; 2022; 19():3. PubMed ID: 35541032
[TBL] [Abstract][Full Text] [Related]
10. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Carcinoma in Effusions.
Shidham VB
Cytojournal; 2022; 19():4. PubMed ID: 35541033
[TBL] [Abstract][Full Text] [Related]
12. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions.
Chen CJ; Chang SC; Tseng HH
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054
[TBL] [Abstract][Full Text] [Related]
13. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
14. Proliferative index using Ki-67 index in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid.
Moghaddam NA; Rahmani A; Taheri D; Desfuli MM
Adv Biomed Res; 2012; 1():29. PubMed ID: 23210088
[TBL] [Abstract][Full Text] [Related]
15. Lamellar Inclusions within Hyperplastic Endoplasmic Reticulum in Benign Mesothelial Cells.
Haefliger S; Jain D; Menter T; Vlajnic T; Savic Prince S; Hopfer H; Mihatsch MJ; Bubendorf L
Acta Cytol; 2020; 64(6):572-576. PubMed ID: 32599592
[TBL] [Abstract][Full Text] [Related]
16. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
17. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
18. Quantitative light microscopy of atypical mesothelial cells and malignant cells in ascitic fluid.
van de Molengraft FJ; van 't Hof MA; Herman CJ; Vooijs PG
Anal Quant Cytol; 1982 Sep; 4(3):217-20. PubMed ID: 7149486
[TBL] [Abstract][Full Text] [Related]
19. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
20. Serous fluid: Metastatic sarcomas, melanoma, and other non-epithelial neoplasms.
Pantanowitz L; Chivukula M
Cytojournal; 2022; 19():15. PubMed ID: 35510115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
